MedTrace Logo

Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158

NCT01533961 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2015-09-18

No results posted yet for this study

Summary

This study is aimed at assessing the tolerability and pharmacokinetic parameters of SCYX-7158 in healthy volunteers. In animal models of both acute and chronic experimental Trypanosomiasis infections, SCYX-7158 shows highly promising efficacy.

Conditions

  • Trypanosomiasis
  • Trypanosomiasis, African
  • Protozoan Infections
  • Parasitic Diseases

Interventions

DRUG

SCYX-7158

DRUG

Placebo

Sponsors & Collaborators

  • Drugs for Neglected Diseases

    lead OTHER

Principal Investigators

  • Antoine Tarral, MD · Drugs for Neglected Diseases initiative

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01533961 on ClinicalTrials.gov